Profile data is unavailable for this security.
About the company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
- Revenue in USD (TTM)0.00
- Net income in USD-192.60m
- Incorporated2018
- Employees74.00
- LocationVentyx Biosciences Inc12790 El Camino Real, Suite 200SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 945-2393
- Fax+1 (302) 655-5049
- Websitehttps://ventyxbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc | 301.87m | -59.29m | 193.89m | 249.00 | -- | -- | -- | 0.6423 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 194.62m | 65.00 | -- | 3.99 | -- | 6.95 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4683 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 197.26m | 400.00 | -- | 0.5083 | -- | 0.1458 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 201.88m | 76.00 | -- | 18.02 | -- | 158.53 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 202.73m | 110.00 | -- | 1.50 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 203.04m | 74.00 | -- | 0.6613 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 203.05m | 274.00 | -- | 0.9788 | -- | 2.85 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 203.19m | 140.00 | -- | 26.27 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Metagenomi Inc | -100.00bn | -100.00bn | 207.93m | 237.00 | -- | 0.7544 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 209.60m | 57.00 | -- | 0.7776 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 214.23m | 128.00 | -- | 1.02 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 214.84m | 137.00 | -- | 1.70 | -- | 2.38 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -25.20 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Codexis Inc | 74.23m | -65.13m | 215.20m | 174.00 | -- | 2.71 | -- | 2.90 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Medifast Inc | 897.81m | 67.76m | 215.57m | 634.00 | 3.18 | 1.02 | 2.66 | 0.2401 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Data as of Jun 14 2024. Currency figures normalised to Ventyx Biosciences Inc's reporting currency: US Dollar USD
44.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Advisors LLCas of 31 Mar 2024 | 5.76m | 8.17% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.61m | 5.12% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.49m | 4.95% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 3.17m | 4.50% |
| Tang Capital Management LLCas of 31 Mar 2024 | 3.10m | 4.40% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 2.71m | 3.84% |
| Point72 Asset Management LPas of 31 Mar 2024 | 2.53m | 3.59% |
| Schonfeld Strategic Advisors LLCas of 31 Mar 2024 | 2.37m | 3.36% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 2.35m | 3.34% |
| Redmile Group LLCas of 31 Mar 2024 | 2.16m | 3.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
